An investing piece argues Lilly's future may rest on three drugs in its pipeline beyond Zepbound. The drugs aren't named in the preview.
Recap by typeshit. Full story at The Globe and Mail.
12:50
Alex Wallace, who bills himself as a peptide expert, gives his response to what Dr. Mike has said about peptides. Details beyond the title are thin.
A search result from Polskie Radio on the approval status of tirzepatide for weight loss, with no further detail provided beyond the question itself.
A Facebook post credits Novo Nordisk's GLP-1 drugs with strong results in obesity and type 2 diabetes, plus lower risk of other conditions.
Lilly's tirzepatide shot Zepbound now has FDA approval in a KwikPen format for weight management. Tap through for details on the new pen.
Oasis Health says Peptides For Sale passed none of 23 tests, with vials of BPC-157 and semaglutide that weren't what the label said or fell short on purity.
CancerNetwork brought together oncology clinicians and a pharmacist to discuss whether GLP-1 drugs are safe for people with breast cancer.
Loading…